Based on our long-standing collaboration with myriamed GmbH and the successful establishment of an AI-powered screenable disease model for dilated cardiomyopathies, we proudly present our program-based spin-off. Myrtil Biotechnologies will conduct a large-scale screening campaign in order to identify new MOAs, targets and therapeutic molecules for next generation medicine and for the benefit of patients.
For more information, please read our press release:
